Table 1.
Baseline clinical characteristics of the persistent AF stratified according to gender
| Characteristic | Total (106) | Male (77) | Female (29) | p value |
|---|---|---|---|---|
| Age, years | 60.4 ± 10.3 | 58.6 ± 10.4 | 65.1 ± 8.7 | 0.003 |
| BMI, kg/m2 | 27.1 ± 3.9 | 27.3 ± 4.0 | 26.6 ± 3.8 | 0.398 |
| AF duration, months | 43.0 ± 46.6 | 43.6 ± 48.6 | 41.4 ± 41.5 | 0.831 |
| Medical history | ||||
| CAD, n (%) | 12 (11.3) | 10 (13) | 2 (6.9) | 0.38 |
| HTN, n (%) | 64 (60.4) | 49 (63.6) | 15 (51.7) | 0.266 |
| DM, n (%) | 15 (14.2) | 13 (16.9) | 2 (6.9) | 0.191 |
| stroke, n (%) | 11 (10.4) | 6 (7.8) | 5 (17.2) | 0.157 |
| Medical therapy at admission | ||||
| Statins, n (%) | 24 (22.6) | 20 (26) | 4 (13.8) | 0.184 |
| ACEI/ARB, n (%) | 23 (21.7) | 15 (19.5) | 8 (27.6) | 0.369 |
| CCB, n (%) | 21 (19.8) | 14 (18.2) | 7 (24.1) | 0.495 |
| Beta-block, n (%) | 22 (19.8) | 17 (22.1) | 5 (17.2) | 0.586 |
| AF related score | ||||
| EHRA score | 0.886 | |||
| 1, n (%) | 12 (11.3) | 8 (10.4) | 4 (13.8) | |
| 2, n (%) | 58 (54.7) | 43 (55.8) | 15 (51.7) | |
| 3, n (%) | 36 (34) | 26 (33.8) | 10 (34.5) | |
| CHA2DS2-VASc score | < 0.001 | |||
| 0 or 1, n (%) | 57 (53.8) | 50 (64.9) | 11 (37.9) | |
| ≥ 2, n (%) | 49 (46.2) | 27 (35.1) | 18 (62.1) | |
| HAS-BLED score ≥ 3, n (%) | 4 (3.8) | 3 (3.9) | 1 (3.4) | 0.915 |
| Echocardiographic parameters | ||||
| LAd, mm | 43.0 ± 5.0 | 43.7 ± 4.6 | 41.3 ± 5.5 | 0.028 |
| LVEF, % | 60.7 ± 6.8 | 59.4 ± 6.9 | 64.1 ± 5.5 | 0.001 |
| Non-PV ablation, n (%) | 61 (57.5) | 47 (61) | 14 (48.3) | 0.238 |
| Recurrence, n (%) | 36 (34) | 20 (26) | 16 (55.2) | 0.005 |
BMI, Body mass index; CAD, coronary artery disease; HTN, hypertension; DM, diabetes mellitus; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; LAd, Left atrium diameter; LVEF, left ventricular ejection fraction